Jay Koyner to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Jay Koyner has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.055
-
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
Score: 0.055